Organized by WHO and CREATE on behalf of the TB/HIV Working Group
TB is the commonest presenting illness and remains a leading cause of death among people living with HIV, both adults and children. HIV is a risk factor for active TB disease in infants and children. Prevention, diagnosis and treatment of TB in children living with HIV are very challenging especially in resource limited settings which carry the brunt of the problem. More severe forms of TB diseases and higher mortality rates are reported in children living with HIV. New and novel TB drugs and TB treatment regimens that are safe, effective, compatible with antiretroviral therapy, and easy to take for the treatment of drug-susceptible and drug-resistant TB in adults and children living with HIV are urgently needed. The World Health Organization and the TB/HIV Working Group in collaboration with the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE) are organizing a meeting to promote high level scientific interchange of ideas and research priorities on the specific issues related to childhood TB and HIV and development of new and novel anti-TB drugs for people living with HIV. This HIV/TB Research meeting will be held in conjunction with the 6th Conference of HIV Pathogenesis, Treatment and Prevention (IAS 2011) in Rome on Sunday July 17, 2011. The meeting will focus on two issues: the development of new and novel anti-TB drugs for people living with HIV, and issues around the prevention, diagnostic, care and treatment of HIV-related TB in children. The meeting will share new data from ongoing studies and discuss potential implementation, discuss controversial issues and identify critical research questions. The meeting will be held in Grand Hotel Ritz Rome, via Chelini 14, located with a walking distance from the Conference centre. Light lunch will be served at the beginning of the meeting.
The meeting is by invitation only and will be on first come first serve basis. If you are interested to participate please send your interest to email@example.com at your earliest convenience but not later than June 30, 2011.